The Methylmalonic Acidemia drugs in development market research report provides comprehensive information on the therapeutics under development for Methylmalonic Acidemia, complete with analysis by ...

The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to ...

Covid vaccine maker Moderna plans to sextuple the number of products it has approved over the next three years, the company ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

If hypoxemia and hypoxia persist, the cellular function in the fetus will switch to anaerobic metabolism, and lactic acid will accumulate (metabolic acidemia). The fact that some degree of ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in ...

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...

Respiratory Syncytial Virus (RSV): Moderna's RSV vaccine, Mresvia, has been approved for adults aged 60 years and older in the U.S. and EU. The company intends to extend the indicated age range of its ...